121 related articles for article (PubMed ID: 19694823)
1. Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations.
Sung MT; Zhang S; Lopez-Beltran A; Montironi R; Wang M; Davidson DD; Koch MO; Cain MP; Rink RC; Cheng L
Histopathology; 2009 Aug; 55(2):161-73. PubMed ID: 19694823
[TBL] [Abstract][Full Text] [Related]
2. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger.
Wild PJ; Giedl J; Stoehr R; Junker K; Boehm S; van Oers JM; Zwarthoff EC; Blaszyk H; Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI; Hartmann A
J Pathol; 2007 Jan; 211(1):18-25. PubMed ID: 17072825
[TBL] [Abstract][Full Text] [Related]
4. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
5. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
[TBL] [Abstract][Full Text] [Related]
6. The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma.
Keck B; Stoehr R; Wach S; Rogler A; Hofstaedter F; Lehmann J; Montironi R; Sibonye M; Fritsche HM; Lopez-Beltran A; Epstein JI; Wullich B; Hartmann A
Int J Cancer; 2011 Jul; 129(2):346-54. PubMed ID: 20878954
[TBL] [Abstract][Full Text] [Related]
7. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
8. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent in situ hybridization as a predictor of relapse in urothelial carcinoma.
García-Peláez B; Trias I; Román R; Pubill C; Banús JM; Puig X
Actas Urol Esp; 2013; 37(7):395-400. PubMed ID: 23453297
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
11. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
12. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L
Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040
[TBL] [Abstract][Full Text] [Related]
13. [Urothelial neoplasms in individuals younger than 20 years show very few genetic alterations and have a favourable clinical outcome].
Giedl J; Wild PJ; Stoehr R; Junker K; Boehm S; van Oers JM; Zwarthoff EC; Blaszyk H; Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI; Hartmann A
Verh Dtsch Ges Pathol; 2006; 90():253-63. PubMed ID: 17867604
[TBL] [Abstract][Full Text] [Related]
14. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
15. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
[TBL] [Abstract][Full Text] [Related]
17. [Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].
Zhang YG; Bi XG; Han YL; Cai Y; Xu X; Wu YP; Yang YL; Ma JH; Zhao P; Jia XM; Wang MR
Ai Zheng; 2007 Feb; 26(2):189-93. PubMed ID: 17298751
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
19. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
20. Frequent association of p53 gene mutation in invasive bladder cancer.
Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]